NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 230 filers reported holding NOVOCURE LTD in Q3 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $300,170 | -31.0% | 7,233 | 0.0% | 0.01% | -37.5% |
| Q1 2023 | $434,993 | -18.0% | 7,233 | 0.0% | 0.01% | -27.3% |
| Q4 2022 | $530,541 | -3.5% | 7,233 | 0.0% | 0.01% | -15.4% |
| Q3 2022 | $550,000 | +66.2% | 7,233 | +51.9% | 0.01% | +62.5% |
| Q2 2022 | $331,000 | -16.2% | 4,762 | 0.0% | 0.01% | 0.0% |
| Q1 2022 | $395,000 | +9.4% | 4,762 | -1.0% | 0.01% | 0.0% |
| Q4 2021 | $361,000 | -35.4% | 4,812 | 0.0% | 0.01% | -38.5% |
| Q3 2021 | $559,000 | -48.0% | 4,812 | -0.7% | 0.01% | -50.0% |
| Q2 2021 | $1,074,000 | +67.8% | 4,845 | +0.1% | 0.03% | +52.9% |
| Q1 2021 | $640,000 | -22.9% | 4,842 | +0.8% | 0.02% | -29.2% |
| Q4 2020 | $830,000 | – | 4,802 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |